Deal-hungry Ipsen is at it again, pledging just over $1 billion for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere Zaiming that is due to start clinical testing next year.

渴望交易的益普生再次行动，承诺出资逾10亿美元，获取由中国先声再明开发的抗体药物偶联物（ADC）癌症治疗药物的权益，该药物预计将于明年开始临床试验。

The drug – codenamed SIM0613 – targets LRRC15, a cell membrane protein that is said to be highly expressed on various tumour types as well as cancer-associated fibroblasts – structural cells that help solid tumours grow but are rarely found on normal, healthy cells.

这种药物——代号为SIM0613——靶向LRRC15，这是一种细胞膜蛋白，据称在多种肿瘤类型以及与癌症相关的成纤维细胞中高度表达——这些结构细胞有助于实体瘤的生长，但在正常健康细胞中很少见。

The protein – which is associated with tumours that arise from mesenchymal tissue like glioblastoma, sarcomas, and melanoma – is thought to influence tumour growth, as well as play a role in resistance to anticancer therapies.

该蛋白与来自间充质组织的肿瘤（如胶质母细胞瘤、肉瘤和黑色素瘤）有关，被认为会影响肿瘤生长，并在抗癌治疗的耐药性中发挥作用。

According to Ipsen, which has development, manufacturing and commercial rights to the ADC outside Greater China, SIM0613 has been designed for superior tumour penetration and has 'robust preclinical efficacy data' backing it up.

根据益普生的说法，该公司拥有ADC在大中华区以外的开发、生产和商业权利，SIM0613旨在实现更优的肿瘤穿透，并且有“强大的临床前疗效数据”支持。

Christelle Huguet, Ipsen's head of R&D, said the deal 'underscores our bold vision to lead innovation and shape the future of oncology' and continues a strategy of adding 'first- and best-in-class therapies' to its early pipeline.

克里斯特尔·乌盖，益普生研发主管，表示该交易“彰显了我们引领创新和塑造肿瘤学未来的宏伟愿景”，并继续执行将其“同类第一和最佳治疗方案”添加到早期研发管线的战略。

It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major player in cancer. Oncology accounted for €1.91 billion of the company's €2.73 billion in sales for the first nine months of this year.

自2020年以来，益普生通过收购20多个早期项目，努力成为癌症领域的主要参与者，这一点值得注意。在今年的前九个月中，该公司销售额达27.3亿欧元，其中肿瘤学贡献了19.1亿欧元。

In the last couple of years alone, it has reached an agreement to buy fellow French firm

近年来，它已经达成了收购另一家法国公司协议

ImCheck Therapeutics

ImCheck Therapeutics

for up to €1 billion ($1.16 billion), adding an antibody-based therapy for acute myeloid leukaemia (AML), and licensed T-cell engager (TCE) therapies from

高达10亿欧元（11.6亿美元），增加了基于抗体的急性髓系白血病（AML）治疗，并从

Biomunex Pharma

生物穆内克斯制药公司

and

和

Marengo Therapeutics

马伦戈治疗公司

in deals valued at up to $610 million and $1.6 billion, respectively.

分别为价值高达6.1亿美元和16亿美元的交易。

Last year also saw it add to its cancer pipeline with two more ADC alliances – with

去年，它还通过另外两项ADC联盟增加了其癌症研发管线——

Foreseen Bio and Sutro Biopharma

预见生物和Sutro生物制药

– and acquire rights outside the US to

——并获取美国以外的权利

Day One Biopharma

第一天生物制药

's brain cancer therapy Ojemda (tovorafenib).

奥杰姆达（托伐拉非尼）脑癌治疗。

Under the terms of the deal with Shanghai-based Simcere Zaiming, Ipsen has manufacturing rights and will assume responsibility for all development activities for SIM0613 outside Greater China, including phase 1 preparation activities and the submission of applications for human trials.

根据与上海先声再明达成的协议条款，益普生拥有生产权，并将负责大中华区以外SIM0613的所有开发活动，包括第一阶段的准备工作和人体试验申请的提交。

Simcere's drug discovery platform also attracted a

先声药业的药物发现平台也吸引了

$1 billion alliance

10亿美元联盟

earlier this year with AbbVie, which acquired rights to SIM0500, a trispecific antibody that targets GPRC5D, BCMA, and CD3 and is in phase 1 testing for relapsed or refractory multiple myeloma.

今年早些时候，AbbVie公司获得了SIM0500的权益，这是一种靶向GPRC5D、BCMA和CD3的三特异性抗体，目前正处于针对复发或难治性多发性骨髓瘤的1期临床试验阶段。